



Long-Term Effects of Developmental Exposure to Oxycodone on Gut Microbiota and Relationship to Adult Behaviors and Metabolism

Zhen Lyu,^a Robert R. Schmidt,^{b,c} Rachel E. Martin,^{b,c} Madison T. Green,^{b,c} Jessica A. Kinkade,^{b,c} Jiude Mao,^{b,c} Nathan J. Bivens,^d Trupti Joshi,^{a,b,e,f} Cheryl S. Rosenfeld^{c,g,h}

^aDepartment of Electrical Engineering and Computer Science, University of Missouri, Columbia, Missouri, USA ^bDepartment of Christopher S Bond Life Sciences Center, University of Missouri, Columbia, Missouri, USA ^cDepartment of Biomedical Sciences, University of Missouri, Columbia, Missouri, USA ^dDepartment of Genomics Technology Core Facility, University of Missouri, Columbia, Missouri, USA ^eDepartment of Health Management and Informatics, University of Missouri, Columbia, Missouri, USA ^fDepartment of MU Institute of Data Science and Informatics, University of Missouri, Columbia, Missouri, USA ^gDepartment of Genetics Area Program, University of Missouri, Columbia, Missouri, USA ^hDepartment of Thompson Center for Autism and Neurobehavioral Disorders, University of Missouri, Columbia, Missouri, Columbia, Missouri, USA

ABSTRACT Opioid drugs are commonly prescribed analgesic to pregnant women. Direct exposure to such drugs may slow gut motility, alter gut permeability, and affect the gut microbiome. While such drugs affect gut microbiome in infants, no study to date has determined whether developmental exposure to such drugs results in longstanding effects on gut microbiota and correspondingly on host responses. We hypothesized developmental exposure to oxycodone (OXY) leads to enduring effects on gut microbiota and such changes are associated with adult neurobehavioral and metabolic changes. Female mice were treated daily with 5 mg OXY/kg or saline solution (control [CTL]) for 2 weeks prior to breeding and then throughout gestation. Male and female offspring pups were weaned, tested with a battery of behavioral and metabolic tests, and fecal boli were collected adulthood (120 days of age). In females, relative abundance of Butyricimonas spp., Bacteroidetes, Anaeroplasma spp., TM7, Enterococcus spp., and Clostridia were greater in OXY versus CTL individuals. In males, relative abundance of Coriobacteriaceae, Roseburia spp., Sutterella spp., and Clostridia were elevated in OXY exposed individuals. Bacterial changes were also associated with predictive metabolite pathway alterations that also varied according to sex. In males and females, affected gut microbiota correlated with metabolic but not behavioral alterations. The findings suggest that developmental exposure to OXY leads to lasting effects on adult gut microbiota that might affect host metabolism, possibly through specific bacterial metabolites or other bacterial-derived products. Further work is needed to characterize how developmental exposure to OXY affects host responses through the gut microbiome.

IMPORTANCE This is the first work to show in a rodent model that *in utero* exposure to an opioid drug can lead to longstanding effects on the gut microbiota when examined at adulthood. Further, such bacterial changes are associated with metabolic host responses. Given the similarities between rodent and human microbiomes, it raises cause for concern that similar effects may become evident in children born to mothers taking oxycodone and other opioid drugs.

KEYWORDS opioids, behavior, brain, microbiota, gut dysbiosis, bacterial changes, gut microbiome, integrative correlation analyses, metabolism, rodents

Editor Gail Rosen, Drexel University **Copyright** © 2022 Lyu et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license.

Address correspondence to Trupti Joshi, JoshiTr@health.missouri.edu, or Cheryl S. Rosenfeld, rosenfeldc@missouri.edu. The authors declare no conflict of interest.

Received 7 April 2022 **Accepted** 14 June 2022 **Published** 7 July 2022

regnant women are commonly prescribed opioid analgesics that are highly addictive. Prescription opioid pain relievers were abused in 2016 by approximately 4% of the United States population (1). Opioid abuse is a primary noncommunicable, public health disorder in the United States (1) with oxycodone (OxyContin [OXY]) being one of the most and abused drug in this class. Opioid use disorder (OUD) is a particular problem in women of child-bearing age. OUD during pregnancy affects approximately 5.6 per 1,000 live births (2). More than 85% of pregnancies with women with OUD are left untreated (3). Infants prenatally exposed to opioids are at risk for neonatal abstinence syndrome (NAS or neonatal opioid withdrawal syndrome) (4). Maternal OUD is associated with poor fetal growth, potential premature birth, low birthweight, and possible congenital defects (5, 6). Infants with NAS have higher neonatal intensive care unit (NICU) admission rates and required longer hospitalization periods (7), resulting in greater health care costs for women with OUD and their infants (7). Even if infants with NAS appear healthy at birth, they may be susceptible to later diseases that a developmental origin of health and disease (DOHaD) origin (8, 9). Developmental exposure to opioid drugs might induce direct effects on offspring brain development and risk for later neurobehavioral disorders (10-17). An underexplored area though is that maternal exposure to opioids may alter the gut microbiome of her offspring and in turn lead to neurobehavioral changes due to affects through the microbiome-gut-brain axis. Brief gestation exposure, days 11 to 13 of gestation of mouse dams to the opioid, hydromorphone (10 mg/kg intraperitoneally) is sufficient to induce gut dysbiosis in her and her offspring (18). In mice, prenatal exposure to the opioid, methadone, induces analogous maternal and infant gut microbial changes (19). Scant amount is known about how early life exposure to OXY can lead to longstanding effects on gut microbiota and whether these are associated with adult behaviors and metabolism. We hypothesized that developmental exposure of mice to OXY induces long-term gut dysbiosis and such bacterial changes are linked to previously described neurobehavioral and metabolic alterations seen in adult offspring (20). To test this hypothesis, fecal boli were collected at adulthood from offspring exposed during the prenatal period to OXY or vehicle control (CTL), bacterial DNA isolated, and 16s rRNA sequencing was performed. Integrative correlation analyses were used to link bacterial alterations to our previously reported neurobehavioral results (20).

RESULTS

General microbiome features. We first considered whether OXY exposure affected overall α - and β - diversity. As determined by Simpson and Shannon, OXY exposure in females and males did not affect overall α -diversity relative to CTL (SAL) counterparts (Fig. S1). Based on the operational taxonomic unit (OTU) bar plot, no overt differences were observed in β - diversity based on offspring sex and OXY exposure (Fig. S2; Data Set 1). PCoA plot showed greater segregation between OXY and CTL male groups relative to PCoA plot comparing the results of these two groups in female progeny. PCoA plots revealed slight differences between OXY females versus CTL females and OXY males versus CTL males with PERMANOVA *P*-value for females and males 0.4 and 0.08, respectively (Fig. 1). The PCoA plots revealed no overall sex differences for CTL males versus CTL females and OXY exposed males versus OXY exposed females with PERMANOVA *P*-values of 0.1 and 0.7, respectively (Fig. S3).

Specific bacterial changes. MetagenomeSeq was used to identify specific bacterial differences based on offspring sex and prenatal exposure to OXY or SAL control vehicle. In females, relative abundance of *Butyricimonas* spp., Bacteroidetes, *Anaeroplasma* spp., TM7, *Enterococcus* spp., and Clostridia were greater in OXY versus CTL (SAL) exposed individuals, whereas *Clostridium* spp. was greater in the CTL group (Fig. 2). Comparison of the male groups revealed greater number of bacterial differences. Relative abundance of Coriobacteriaceae, *Roseburia* spp., *Sutterella* spp., and Clostridia were elevated in OXY exposed individuals (Fig. 3). In contrast, *Clostridium* spp., *Staphylococcus* spp., Bacilli, Firmicutes, Prevotella, Butyricicoccus, Peptococcaceade, *Clostridium* spp., *Enterococcus*



FIG 1 Three-dimensional PCoA plots to show β -diversity. PERMANOVA values for OXY exposed females versus CTL females and OXY exposed males versus CTL males 0.4 and 0.08, respectively. Replicates tested include n = 6 OXY exposed females, six CTL females, five OXY exposed males, and 11 CTL males.

spp., Desulfovibionaceae, *Turicibacter* spp., and Lactobacillales had greater relative abundance in CTL versus OXY exposed individuals.

We also compared results in CTL males versus CTL females and OXY exposed males to OXY exposed females to determine if developmental exposure to OXY affected sexually dimorphic differences in gut microbiota. Relative abundance of *Corynebacterium* spp., *Anaeroplasma* spp., Firmicutes, *Clostridium* spp., Bacteroidetes, and Bacilli was greater in CTL males versus CTL females, whereas Coriobacteriaceae was increased in CTL females compared with CTL males (Fig. S4). In contrast, relative abundance of Corynebacterium and Coriobacteriaceae was greater in OXY exposed males versus OXY exposed females. Peptococcaeceae, *Enterococcus* spp., *Prevotella* spp., *Butyricicoccus* spp., *Staphylococcus* spp., and Staphylococcaeceae (Fig. S5.)

PiCRUSt analysis. PiCRUSt analysis was done to examine potential metabolic pathways that might be altered based on the identified bacterial changes. While no metabolic pathways reached statistical significance in the females, the ones that showed the strongest positive correlation where glycolysis and sucrose degradation with *Clostridium* spp. (Fig. 4). Conversely, those that showed the greatest negative correlation in females were L-threonine metabolism with Bacteroidetes and purine deoxyribonucleotides *de novo* biosynthesis with TM7. In males, the one inverse correlation that

	groupSal	group	groupSal	adjPvalues
k_Bacteria.p_Bacteroidetes.c_Bacteroidia.o_Bacteroidales.fOdoribacteraceaeg_Butyricimonas	-7.690963679	Ox	7.69096368	1.22E-05
k_Bacteria.p_Firmicutes.c_Erysipelotrichi.o_Erysipelotrichales.f_Erysipelotrichaceae.g_Clostridium	10.61847534	Sal	10.6184753	1.22E-05
k_Bacteria.p_Bacteroidetes.p_Bacteroidetes_x_L3.p_Bacteroidetes_x_L4.p_Bacteroidetes_x_L5.p_Bacteroidetes_x_L6	-6.623720243	Ox	6.62372024	9.37E-05
k_Bacteria.p_Tenericutes.c_Mollicutes.o_Anaeroplasmatales.f_Anaeroplasmataceae.g_Anaeroplasma	-6.819647329	Ox	6.81964733	0.00015629
k_Bacteria.p_TM7.c_TM7_3.o_CW040.f_F16.f_F16_g_L6	-5.372238511	Ox	5.37223851	0.00395341
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Enterococcaceae.g_Enterococcus	-5.735688998	Ox	5.735689	0.01344318
k_Bacteria.p_Firmicutes.c_Clostridia.c_Clostridia_x_L4.c_Clostridia_x_L5.c_Clostridia_x_L6	-6.253792091	Ox	6.25379209	0.04388788



FIG 2 MetagenomeSeq analysis to determine bacterial differences between OXY females versus CTL females.

	groupSal	grou groupSal	adjPvalues
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Clostridium	13.27388508	Sal 13.27388508	1.52E-08
k_Bacteria.p_Firmicutes.c_Bacilli.o_Bacillales.f_Staphylococcaceae.g_Staphylococcus	6.400243044	Sal 6.400243044	2.34E-05
$\label{eq:label} k_Bacteria.p_Actinobacteria.c_Coriobacteria.a.sc_Coriobacteriales.f_Coriobacteriaceae.f_Coriobacteriaceae.g_L6$	-8.165309754	Ox 8.165309754	3.24E-05
k_Bacteria.p_Firmicutes.c_Bacilli.c_Bacilli_x_L4.c_Bacilli_x_L5.c_Bacilli_x_L6	7.625316517	Sal 7.625316517	3.24E-05
k_Bacteria.p_Firmicutes.p_Firmicutes_x_L3.p_Firmicutes_x_L4.p_Firmicutes_x_L5.p_Firmicutes_x_L6	7.62167045	Sal 7.62167045	3.24E-05
k_Bacteria.p_Bacteroidetes.c_Bacteroidia.o_Bacteroidales.f_Prevotellaceae.g_Prevotella	5.552160487	Sal 5.552160487	0.000654194
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Lachnospiraceae.g_Roseburia	-4.951994992	Ox 4.951994992	0.000939825
$eq:linear_line$	-8.155849609	Ox 8.155849609	0.000939825
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Ruminococcaceae.g_Butyricicoccus	5.302019878	Sal 5.302019878	0.00182629
k_Bacteria.p_Firmicutes.c_Clostridia.c_Clostridia_x_L4.c_Clostridia_x_L5.c_Clostridia_x_L6	-7.682798127	Ox 7.682798127	0.001908396
k_Bacteria.p_Firmicutes.c_Clostridia.o_Clostridiales.f_Peptococcaceae.f_Peptococcaceae_g_L6	7.341280612	Sal 7.341280612	0.00228498
k_Bacteria.p_Firmicutes.c_Erysipelotrichi.o_Erysipelotrichales.f_Erysipelotrichaceae.g_Clostridium	6.535620271	Sal 6.535620271	0.009284327
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.f_Enterococcaceae.g_Enterococcus	6.350651135	Sal 6.350651135	0.011730997
$\label{eq:label} k_Bacteria.p_Proteobacteria.c_Deltaproteobacteria.o_Desulfovibrionales.f_Desulfovibrionaceae.f_Desulfovibrionaceae_g_L6$	2.586215791	Sal 2.586215791	0.037683969
k_Bacteria.p_Firmicutes.c_Bacilli.o_Turicibacterales.f_Turicibacteraceae.g_Turicibacter	3.030474148	Sal 3.030474148	0.040340526
k_Bacteria.p_Firmicutes.c_Bacilli.o_Lactobacillales.o_Lactobacillales_x_L5.o_Lactobacillales_x_L6	3.400587418	Sal 3.400587418	0.046446395





was statistically significant at P < 0.05 was myo-, chiro-, and scyllo-inositol degradation with Lactobacillales (Fig. 5). Positive correlations that approached significance were Coriobacteriaceae with polymyxin resistance, phospho-respiration, formaldehyde assimilation, superfamily of sulfoacetylation, 4-aminobutanoate degradation, and superfamily of polyamine biosynthesis. Firmicutes showed a strong trend to being inversely correlated with pyridine deoxyribonucleotide phosphorylation.

Integrative correlation analyses. In previous studies, we found that developmental exposure to OXY resulted in socio-communication deficits that persisted from weaning through adulthood (20). Such offspring also had cognitive impairments, reduced voluntary physical activity, and weighed more than CTL counterparts. In the hippocampus, OXY-exposed offspring had altered expression of genes encoding opioid receptors and those involved in serotonin signaling. We did not, however, detect any signs of substance abuse or dependency, although this was not explicitly tested in this prior work.

As these were the same offspring used in this previous study (20), we next used mixOmics analyses with $a \ge 0.70$ correlation value, which is considered stringent, to examine for associations between gut microbiota changes and these adult parameters. This approach revealed several positive and negative correlations relative to gut microbial changes in both female and male groups. In females, Bacteroidetes, Anaeroplasma spp., and Butyricimonas spp. positively correlated with fat weight (Fig. 6). Clostridium spp. was positively associated with PedMeters (total meters walked while in the indirect calorimetry unit). Conversely, Bacteroidetes, Anaeroplasma spp., and Butyricimonas spp. were negatively linked with lean percentage and total energy expenditure (EE) in the indirect calorimetry unit. Clostridium spp. was inversely associated with walking percentage in the indirect calorimetry unit and mean speed and distance traveled in the Barnes maze. In males, Prevotella and Staphylococcus spp. were positively associated with mean speed in the Barnes maze (Fig. 7). Butyricicoccus was inversely correlated with total water percentage. The one significant metabolic pathway in males, myo-, chiro-, and scyllo-inositol degradation, negatively correlated with total water and lean percentages.



FIG 4 Bacterial metabolic and other pathway differences in the fecal microbiome of OXY exposed females versus CTL females. As described in Fig. 7 of Ma et al. (51), correlations between the PICRUSt-generated functional profile and QIIME II-generated genus level bacterial abundance were calculated and plotted against treatment group. Those genera that were identified by MetagenomeSeq as being different (Continued on next page)

5

DISCUSSION

The goals of the current study were to investigate whether developmental exposure of mice to OXY results in persistent changes in gut microbiota that extend into adulthood and are sex-dependent. Second, we sought to determine whether such gut microbiota changes might be linked to changes in metabolic pathways and previously identified neurobehavioral and metabolic disruptions reported at adulthood in male and female offspring prenatally exposed to OXY (20). Past mice studies have shown that OXY exposure can lead to direct maternal and infant effects (18, 19). However, the current study is the first to explore whether such exposure can result in long-term gut dysbiosis changes. In females developmentally exposed to OXY, the primary gut bacterial changes were relative abundance of Butyricimonas spp., Bacteroidetes, Anaeroplasma spp., TM7, Enterococcus spp., and Clostridia. Butyricimonas spp. are Gram-negative and anaerobic bacteria associated with butyrate production (21, 22). Women with nonalcoholic fatty liver syndrome (NAFLD) have also been reported to have an increase in this bacterial genus (23). Rats treated with the Antidepressants fluoxetine or amitriptyline also show greater relative abundance of Butyricimonas spp. (24). Humans with Parkinson's disease who show mild cognitive impairment (PD-MCI) have elevations in this bacterium (25). Butyricimonas spp. relative numbers are greater in a cohort of patients with autism spectrum disorder (ASD) relative to children without this disorder (26). Taken together, the collective findings suggest that other pharmaceutical agents may influence the abundance of this bacterium that has been linked to metabolic and neurobehavioral diseases.

Bacteroidetes relative abundance is also greater in simian immunodeficiency virus (SIV)-infected rhesus macaques treated with morphine (27). In mice, proliferation of *Enterococcus faecalis* correlates with gut dysbiosis due to morphine treatment (28). Nosocomial infections with *Clostridium difficile* (CDI) have been disproportionately seen in chronic opioid users (29). Another study found that the odds risk ratio was significantly elevated in those taking opioid drugs (30). Such findings are supported by a preceding study (31). The primary caveat to our current findings relative to previous reports is that our bioinformatics analysis only revealed that it was a Clostridia that was elevated in the OXY exposed groups, and thus, it could be a pathogenic or nonpathogenic microorganism. Further studies, including metagenome sequencing are needed to further characterize and type the specific bacteria identified based on this initial screening. The above studies are based on direct exposure to opioids, whereas the females used in this study were only exposed prior to birth. Notwithstanding, our results in light of past findings suggest that opioids might induce similar bacterial changes regardless of exposure window.

Gut bacterial changes in OXY exposed male offspring differed from those of their female siblings. However, Clostridia was elevated in male and female offspring developmentally exposed to OXY. Male offspring also had increased relative abundance of Coriobacteriaceae, *Roseburia* spp., and *Sutterella* spp. Relative reductions in *Clostridium* spp., *Staphylococcus* spp., Bacilli, Firmicutes, Prevotella, Butyricicoccus, Peptococcaceade, *Clostridium* spp., *Enterococcus* spp., Desulfovibionaceae, *Turicibacter* spp., and Lactobacillales were noted in these males. *Roseburia* relative abundance has been shown to be greater in the gut microbiota of pregnant women with ketonuria (32). Butyrate production by *Roseburia* may increase serum ketone levels in both the mother and her fetus. Maternal obesity during pregnancy may also increase this bacterium (33). Another pregnancy cohort study revealed that the abundance of *Staphylococcus* relative

FIG 4 Legend (Continued)

between the two groups are depicted. Bacteria that are highlighted had increased relative amounts in OXY exposed group. Metabolic pathway designations are delineated at the top of the figure. Shading intensity and size of the circles indicates the Kendall rank correlation coefficient between matrices. Red indicates a positive correlation, whereas blue designates a negative correlation. Red squares surrounding the circles are indicative of a *P* value \leq 0.05, although none were present for this comparison. Legend for the quantitative scores associated with the range of blue to red colors is listed below the figure. Legend for the scores associated with the range of blue to red colors is listed below the figure.



FIG 5 Bacterial metabolic and other pathway differences in the fecal microbiome of OXY exposed males versus CTL males. As described in Fig. 7 of Ma et al. (51), correlations between the PICRUSt-generated (Continued on next page)

mSystems



FIG 6 Circos plot correlations between gut bacterial, metabolites, and behavioral and metabolic parameters in OXY exposed females versus CTL females. Red lines in the center indicate a positive correlation. In contrast, blue lines indicate a negative correlation. Results for CTL (SAL) females are indicated with an orange line outside the circle. Blue line indicates results for OXY females. The color of the line further from the circle indicates the group where these results are greater.

to Clostridium, *Roseburia*, and Coriobacteriaceae were positively correlated with fasting blood glucose (34).

Reduced relative abundance of *Roseburia* has been reported in humans on opioid drugs (35). Firmicutes is reduced but *Prevotella* relative abundance was found to be increased in the above study testing effects of opioids on rhesus macaques (27). In a study with African American men, interrelationships were found between type 2 diabetes mellitus, metformin treatment, and opioid usage for Bifidobacterium and *Prevotella* genera (36). Maternal exposure to the opioid, methadone, resulted in similar bacterial changes in the mother and her offspring with Lachnospiraceae NK4A136 genus being one of the primary genera associated with several of the shared features (19). This group though did not show changes in relative abundance in OXY exposed male or female offspring. Differences in the previous studies testing effects of opioids and the current results could be attributed to generational effects, type of opioid, and age of offspring examined (birth versus adulthood).

Based on the bacterial changes identified in female and male offspring, our prediction was that PICRUSt would reveal potential alterations in short-chained fatty acids, including butyric and propionic acid. However, such predictions were not identified. Instead, pathways enriched, although they did not reach statistical significance, in female offspring were carbohydrate and threonine metabolism and nucleotide biosynthesis. The one metabolic pathway that was significant in males and correlated with Lactobacillales, which showed relative reductions in OXY exposed males, was myo-, chiro-, and scyllo-inositol degradation. Inositols are polyol that exist in different stereoisomers, e.g., myo-inositol, d-chiro- and scyllo- forms. Supplementation of such compounds may

FIG 5 Legend (Continued)

functional profile and QIIME II-generated genus level bacterial abundance were calculated and plotted against treatment group. Those genera that were identified by MetagenomeSeq as being different between the two groups are depicted. Bacteria that are highlighted had increased relative amounts in OXY exposed group. Metabolic pathway designations are delineated at the top of the figure. Shading intensity and size of the circles indicates the Kendall rank correlation coefficient between matrices. Red indicates a positive correlation, whereas blue designates a negative correlation. Red squares surrounding the circles are indicative of a *P* value ≤ 0.05 , although none were present for this comparison. Legend for the scores associated with the range of blue to red colors is listed below the figure. Legend for the scores associated with the range of blue to red colors is listed below the figure.

mSystems



FIG 7 Circos plot correlations between gut bacterial, metabolites, and behavioral and metabolic parameters in OXY exposed males versus CTL males. Red lines in the center indicate a positive correlation. In contrast, blue lines indicate a negative correlation. Results for CTL (SAL) males are indicated with an orange line outside the circle. Blue line indicates results for OXY males. The color of the line further from the circle indicates the group where these results are greater.

hold therapeutic promise for a variety of diseases, especially neurological disorders. Provisioning of a mouse model for AD with scyllo-inositol reduced plague formation within the brain (37), decreased amyloid load, and astrocyte activation in the cortex (37, 38). In the current study, decrease in the overall abundance of Lactobacillales might suggest an increase in degradation of these inositols with resulting reductions in such stereoisomer forms. Based on the above studies, our prediction that such reductions would correlate with neurobehavioral outcomes. However, the mixOmics analyses only revealed an inverse correlation with metabolic phenotypes, lean and total water percentages. Follow-up metabolomic analyses using various mass spectrometry approaches are needed to confirm these predictions.

While no study to date has examined whether developmental exposure to opioids affects later metabolomic profiles, a few studies considered effects of direct exposure on the brain metabolome profile. Metabolome screening of the cerebrum in mice treated with tramadol revealed changes in metabolites associated with oxidative damage, inflammation, and disruption of the GABA neurotransmitter system (39). In rhesus macaques, chronic morphine exposure results in neural alterations in neurotransmitters and metabolites associated with membrane and energy metabolism (40).

While some of the neurobehavioral and metabolic changes in the offspring might be ascribed to alterations in the gut microbiota, they could also be due to direct effects on fetal brain development as OXY and other opioid drugs can readily cross the placenta (41, 42), be taken up by placental cells (trophoblasts) (43), and transferred to the fetus where it can affect fetal brain development. In previous work, we have shown that OXY exposure can affect mouse placental morphology and gene expression patterns (44) that in turn might also the initial stage of fetal brain growth through the placenta-brain axis (45).

The limitations of the current study are that we did not collect fecal samples from the dam to determine whether direct and developmental exposure to OXY induces similar changes. It would also have been of interest to examine and compare gut microbiota changes throughout the life span in exposed male and female offspring. However, our primary goal of these studies was to link those gut microbiota changes identified at adulthood with behavioral and metabolic alterations at this time. Future studies thus include examining gut microbiota throughout the life span in the presence and absence of opioids, such as OXY, as well as determining the microbial composition from the F0. We also seek to determine whether other opioid drugs, including agonistic and antagonistic agents, have similar effects as OXY. While 16s rRNA sequencing provides generation information on bacteria that might be affected by this opioid, it does not indicate how this drug affects bacterial genomes. For this reason, we will use metagenome seq in future studies. As detailed, future work will also examine the effects of developmental exposure to opioids on host and bacterial metabolites by using a variety of metabolomic approaches.

In conclusion, these studies are the first to show that developmental exposure to OXY alters the gut microbial profile at adulthood. The specific bacteria affected by this opioid show sex-dependent differences. Relative abundance of Clostridia was elevated in both males and females exposed to OXY. Bacterial changes were also associated with predictive metabolite pathway alterations that also varied according to sex. In both males and females, affected gut microbiota correlated with metabolic but not behavioral alterations. The findings suggest that OXY induced changes in the gut microbiota might affect host metabolism, which could be through specific bacterial metabolites or other bacterial-derived products. Further work is needed to characterize how developmental exposure to OXY affects host responses directly and through the gut microbiome.

MATERIALS AND METHODS

Animals and treatments. Current animal experiments were approved by our Institutional Animal Care and Use Committee (ACUC, Protocol #9590). All studies conformed to the NIH Guidelines for the Care and Use of Laboratory Animals. Seven-week-old male and female CF1 mice were ordered from Envigo (Madison, WI), and females were habituated to the animal facility for 1 week prior to being placed on one of two treatments. Mice were maintained on a 12-h light: 12-h dark cycle. The average room temperature is 70°F, and the humidity range is between 30% and 70%. Female mice were randomly assigned to be in the OXY (Catalogue # O1378; Sigma Chemical, St. Louis, MO) or saline CTL groups. At 8 weeks of age, the OXY group received 5 mg OXY/kg body weight in 0.9% saline with an average volume of 0.1 mL injected intraperitoneally (IP) between in the morning daily for 2 weeks prior to breeding and then throughout gestation. During this time, the CTL group received comparable IP injection volumes of 0.9% saline. Females were weighed weekly throughout the course of the experiment, and the dose of OXY was adjusted to continue to provide a dose of 5 mg/kg. This dose and route of administration (IP) was used based on past findings that showed such concentrations mimic those achieved in humans with OUD (46-48). No ill effects were noted in mice treated with OXY or saline control IP injections. No differences in appetite or weight gain were noted for females in the OXY or saline control group. The treatments commenced 2 weeks prior to breeding to include the periconceptional period, as this may be important in preimplantation embryonic development (49, 50). Animals were provided food and water ad libitum and fed an AIN93G phytoestrogen-free diet (Envigo, Madison, WI) to reduce any exogenous estrogen exposure.

Breedings. After 2 weeks of being treated daily with OXY or CTL solutions, females were paired with potential CF1 breeder males and examined the next morning for a vaginal plug. The day a vaginal plug was observed was considered E 0.5. If no vaginal plug was observed in the morning, males were placed in separate cages and repaired that evening with females. Female mice were maintained on their respective treatments until parturition. No differences in fertilization rates or pregnancy success rate were noted between the two maternal groups. One male and one female offspring from each litter (n = 13 male and 13 females for CTL and 10 male and 10 female mice for OXY group) were randomly chosen to undergo behavioral and metabolic testing. The same male and female offspring from each litter were used for all of the behavioral and metabolic assessments and gene expression studies.

Collection of fecal samples and isolation of fecal microbial DNA. Same sex siblings were housed together until the time of fecal collection. At 120 days of age, each animal was placed in a cage alone without any bedding. Four to five fecal boli were collected from each animal and placed in sterile 2 mL cryogenic vials (Corning Incorporated, Corning, NY) and placed in liquid N₂ until they were transferred to a -80° C freezer. Thereafter, the samples were stored until they were used for bacterial isolation and gut microbiota analysis. The fecal microbial DNA was isolated from a portion of the fecal boli collected using the Invitrogen Pure Link Microbiome DNA purification kit (Thermo Fisher Scientific, Waltham, MA) and in accordance with the manufacturer's protocol. The quantity of DNA isolated was measured using Qubit 3.0 Fluorometer (Life Technologies, Grand Island, NY). The number of replicates tested is comparable to other studies examining how *in utero* environmental changes can affect gut bacterial populations and have shown that such sample sizes can result in statistical differences between offspring groups (51, 52).

16S rRNA sequencing. The University of Missouri (MU) DNA Core Facility prepared bacterial 16S ribosomal DNA amplicons from extracted fecal DNA by amplification of the V4 hypervariable region of the 16S rDNA with universal primers (U515F/806R) flanked by Illumina standard adapter sequences (53, 54). The rest of the procedures were performed as described previously (55, 56). The resulting amplicon pool was analyzed by using the Advanced Analytical Fragment Analyzer automated electrophoresis system, quantified with a Qubit fluorometer using a quant-iT HS dsDNA reagent kit (Invitrogen), and diluted according to Illumina's standard protocol for sequencing on the MiSeq.

Paired-end Illumina MiSeq DNA reads were joined, combined, and imported from Casava 1.8 pairedend demultiplexed fastq format to QIIME2 (57) format using the "qiime tools import" method from QIIME 2. Samples having less than 200 reads were excluded from the further analysis as the few reads typically represent transcriptional noise. This retains for 10 female samples for OXY group, nine female samples for saline control group, eight male samples for OXY group, and 12 male samples for saline control group. For the sequence quality control, the "Deblur" plugin in QIIME2 was utilized to filtering the sequences with –p-trim-length assigned 120. The rooted phylogenetic tree and unrooted tree were created using the "qiime phylogeny align-to-tree-mafft-fasttree" command.

Bioinformatics analyses. Microbial diversity was evaluated by running alpha diversity and beta diversity on the OTU tables. Diversity analysis was conducted for male and female groups using the q2-diversity plugin from QIIME2. The diversity comparisons were assessed between OXY and saline control for male and female group. For alpha diversity, Simpson diversity index (a quantitative measure of community richness) and Shannon diversity index rarefaction plots were generated using the "qiime diversity alpha-rarefaction" command supported by the QIIME2. Measurements of beta-diversity were facilitated by the QIIME2 command "qiime diversity core-metrics-phylogenetics" with p-sampling-depth assigned with 41,980. The permutational MANOVA (permanova) value was calculated using "qiime diversity beta-group-significance" command. For the taxonomic analysis, we used a pretrained Naïve Bayes classifier and the "q2-feature-classifier" plugin. This classifier was created based on the Greengenes 13_8 99% OTUs.

There were initially 10 OXY exposed females, nine CTL females, eight OXY exposed males, and 12 CTL males prior to filtering out samples with low reads quality, and criteria based on the PCoA analysis program. Therefore, for the PCoA analysis and subsequent analyses, there remained six OXY exposed females, six CTL females, five OXY exposed males, and 11 CTL males.

MetagenomeSeq (58) was used to determine the OTUs that are differentially abundant between OXY and saline CTL groups, CTL males versus CTL females, and OXY exposed males versus OXY exposed females. This program first creates the MRexperiment object taking the OTU table and metadata as input. The cumNormStatFast and cumNorm functions were used to calculate the normalization factors and normalized count matrices. After taking care of normalization, it utilized the fitZig (Zero-inflated Gaussian mixture model) function to detect the significant differentially abundant OTUs with *P*-value < 0.05.

Functional metagenomics predictions. Bacterial metabolic characterization of sample types was facilitated with q2-picrust2 (59–64) (the phylogenetic investigation of communities by reconstruction of unobserved states). It uses "qiime picrust2 full-pipeline" command to get Enzyme Commission (EC), Kyoto Encyclopedia of Genes and Genomes Orthologs (KEGG), and MetaCyc pathway prediction. The final output files, including EC, KEGG, and pathway prediction in QZA format. To export the result, "qiime tools export" command was used to convert the QZA file to BIOM format, then use "biom convert" to convert BIOM file to plain-text for downstream analysis.

DESeq2 (65) was used to highlight the pathway terms that are significantly differentially abundant between OXY and CTL saline group. DESeqDataSetFromMatrix function was first used to create the experiment object with count matrix and metadata file. The differential expression analysis was estimated by DESeq function based on the Negative Binomial (a.k.a. Gamma-Poisson) distribution. This function first calculates the size factors and dispersion and then apply the Negative Binomial GLM fitting and Wald statistics test. Shrunken log_{2-fold} changes (LFC) and SE was added to the results table from DESeq using lfcShrink function. Finally, filtering the significant terms with adjusted *P*-value < 0.05.

Correlation of taxa abundance and metabolic activity abundance. To correlate the taxa abundance with metabolic characteristics of sample types, a custom R script provided as a gift from Dr. Jun Ma and Kjersti Aagaard-Tillery, Baylor College of Medicine, Houston, TX was used (51), as we have done previously (55, 66, 67). In these figures, the correlation of the abundance of taxa (from the OTU table) with the predicted metabolic function (from MetaCyc pathways as determined by q2-picrust), was calculated with the R stats function cort.est (https://cran.r-project.org/), using the Kendall method, a rank-based measure of association. The cor. test function outputs the correlation coefficient and significance of a comparison of an OTU with a pathway term across samples. The matrix of all the correlation values was visualized using the R package corrplot (https://cran.r-project.org/). The area and intensity change together so that larger, darker, circles represent correlation coefficients that are larger in magnitude. The scale to the right of each figure relates those shades of color to the value of the correlation coefficient.

Multiomics integrative correlation analyses. The mixOmics (68) R package was used to correlate the bacterial genera changes simultaneously with body composition, brain histological data, and behavioral results, which enabled the integration of the microbiome, behavioral (social testing, ultrasonic vocalization, Barnes maze, and elevated plus maze, EPM), metabolic phenotyping (EchoMRI and MetRack) and qPCR gene expression results that have been previously reported (20). We conducted sparse discriminant analysis with partial least square regression with function "block.splsda." The circos plot was generated by using the "circosPlot" function with correlations calculated using the method from González et al. and 0.7 correlation was used as the cutoff (69).

Data availability. All the raw sequencing data are available at BioProject link: https://www.ncbi.nlm .nih.gov/bioproject/PRJNA786078.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only. DATA SET S1, XLSX file, 0.03 MB. FIG S1, TIF file, 0.2 MB. FIG S2, TIF file, 1.5 MB. FIG S3, TIF file, 0.1 MB. FIG S4, TIF file, 0.2 MB. FIG S5, TIF file, 0.3 MB.

ACKNOWLEDGMENTS

We appreciate the undergraduate students who assisted with animal husbandry and

general care of the mice colonies.

We declare no conflict of interest.

CSR is supported by NIEHS 1R01ES025547.

REFERENCES

- Reinhart M, Scarpati LM, Kirson NY, Patton C, Shak N, Erensen JG. 2018. The economic burden of abuse of prescription opioids: a systematic literature review from 2012 to 2017. Appl Health Econ Health Policy 16: 609–632. https://doi.org/10.1007/s40258-018-0402-x.
- Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. 2012. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 307:1934–1940. https://doi.org/10.1001/jama.2012.3951.
- Heil SH, Jones HE, Arria A, Kaltenbach K, Coyle M, Fischer G, Stine S, Selby P, Martin PR. 2011. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat 40:199–202. https://doi.org/10.1016/j.jsat.2010.08.011.
- Jones HE, Kaltenbach K, Benjamin T, Wachman EM, O'Grady KE. 2019. Prenatal opioid exposure, neonatal abstinence syndrome/neonatal opioid withdrawal syndrome, and later child development research: shortcomings and solutions. J Addict Med 13:90–92. https://doi.org/10.1097/ADM .0000000000000463.
- CDC. 2019. Basics about opioid use during pregnancy. Accessed https:// www.cdc.gov/pregnancy/opioids/basics.html.
- Yazdy MM, Desai RJ, Brogly SB. 2015. Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet 4:56–70. https://doi.org/10.1055/s-0035-1556740.
- Clemans-Cope L, Lynch V, Howell E, Hill I, Holla N, Morgan J, Johnson P, Cross-Barnet C, Thompson JA. 2019. Pregnant women with opioid use disorder and their infants in three state Medicaid programs in 2013–2016. Drug Alcohol Depend 195:156–163. https://doi.org/10.1016/j.drugalcdep .2018.12.005.
- Grandjean P, Barouki R, Bellinger DC, Casteleyn L, Chadwick LH, Cordier S, Etzel RA, Gray KA, Ha EH, Junien C, Karagas M, Kawamoto T, Paige Lawrence B, Perera FP, Prins GS, Puga A, Rosenfeld CS, Sherr DH, Sly PD, Suk W, Sun Q, Toppari J, van den Hazel P, Walker CL, Heindel JJ. 2015. Life-long implications of developmental exposure to environmental stressors: new perspectives. Endocrinology 156:3408–3415. https://doi.org/10.1210/EN.2015-1350.
- 9. Rosenfeld CS. 2015. The epigenome and developmental origins of health and disease. Elsevier.
- Akbarabadi A, Niknamfar S, Vousooghi N, Sadat-Shirazi MS, Toolee H, Zarrindast MR. 2018. Effect of rat parental morphine exposure on passive avoidance memory and morphine conditioned place preference in male offspring. Physiol Behav 184:143–149. https://doi.org/10.1016/j.physbeh .2017.11.024.
- Goldfarb SS, Stanwood GD, Flynn HA, Graham DL. 2020. Developmental opioid exposures: neurobiological underpinnings, behavioral impacts, and policy implications. Exp Biol Med (Maywood) 245:131–137. https:// doi.org/10.1177/1535370219883601.
- Jantzie LL, Maxwell JR, Newville JC, Yellowhair TR, Kitase Y, Madurai N, Ramachandra S, Bakhireva LN, Northington FJ, Gerner G, Tekes A, Milio LA, Brigman JL, Robinson S, Allan A. 2020. Prenatal opioid exposure: the next neonatal neuroinflammatory disease. Brain Behav Immun 84:45–58. https://doi.org/10.1016/j.bbi.2019.11.007.
- McPherson C, Haslam M, Pineda R, Rogers C, Neil JJ, Inder TE. 2015. Brain injury and development in preterm infants exposed to fentanyl. Ann Pharmacother 49:1291–1297. https://doi.org/10.1177/1060028015606732.
- Mohamed E, Paisley CE, Meyer LC, Bigbee JW, Sato-Bigbee C. 2020. Endogenous opioid peptides and brain development: endomorphin-1 and Nociceptin play a sex-specific role in the control of oligodendrocyte maturation and brain myelination. Glia 68:1513–1530. https://doi.org/10 .1002/glia.23799.

- Ross EJ, Graham DL, Money KM, Stanwood GD. 2015. Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology 40:61–87. https://doi.org/10.1038/npp .2014.147.
- Sanchez ES, Bigbee JW, Fobbs W, Robinson SE, Sato-Bigbee C. 2008. Opioid addiction and pregnancy: perinatal exposure to buprenorphine affects myelination in the developing brain. Glia 56:1017–1027. https:// doi.org/10.1002/glia.20675.
- Vathy I. 1995. Effects of prenatal morphine and cocaine on postnatal behaviors and brain neurotransmitters. NIDA Res Monogr 158:88–114.
- Abu Y, Tao J, Dutta R, Yan Y, Vitari N, Kolli U, Roy S. 2021. Brief hydromorphone exposure during pregnancy sufficient to induce maternal and neonatal microbial dysbiosis. J Neuroimmune Pharmacol https://doi.org/10.1007/s11481-021-10019-2.
- Grecco GG, Gao Y, Gao H, Liu Y, Atwood BK. 2021. Prenatal opioid administration induces shared alterations to the maternal and offspring gut microbiome: a preliminary analysis. Drug Alcohol Depend 227:108914. https://doi.org/10.1016/j.drugalcdep.2021.108914.
- Martin RE, Green MT, Kinkade JA, Schmidt RR, Willemse TE, Schenk AK, Mao J, Rosenfeld CS. 2021. Maternal oxycodone treatment results in neurobehavioral disruptions in mice offspring. eNeuro 8. https://doi.org/10 .1523/ENEURO.0150-21.2021.
- Nguyen TTT, Oshima K, Toh H, Khasnobish A, Fujii Y, Arakawa K, Morita H. 2019. Draft genome sequence of Butyricimonas faecihominis 30A1, isolated from feces of a Japanese Alzheimer's disease patient. Microbiol Resour Announc 8. https://doi.org/10.1128/MRA.00462-19.
- 22. Sakamoto M, Takagaki A, Matsumoto K, Kato Y, Goto K, Benno Y. 2009. Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family 'Porphyromonadaceae' isolated from rat faeces. Int J Syst Evol Microbiol 59:1748–1753. https://doi.org/10.1099/ijs.0.007674-0.
- Shi J, Yang Y, Xu W, Cai H, Wu J, Long J, Cai Q, Zheng W, Flynn CR, Shu XO, Yu D. 2021. Sex-specific associations between gut microbiome and nonalcoholic fatty liver disease among Urban Chinese adults. Microorganisms 9:2118. https://doi.org/10.3390/microorganisms9102118.
- 24. Zhang W, Qu W, Wang H, Yan H. 2021. Antidepressants fluoxetine and amitriptyline induce alterations in intestinal microbiota and gut microbiome function in rats exposed to chronic unpredictable mild stress. Transl Psychiatry 11:131. https://doi.org/10.1038/s41398-021-01254-5.
- Ren T, Gao Y, Qiu Y, Jiang S, Zhang Q, Zhang J, Wang L, Zhang Y, Wang L, Nie K. 2020. Gut microbiota altered in mild cognitive impairment compared with normal cognition in sporadic Parkinson's disease. Front Neurol 11:137. https://doi.org/10.3389/fneur.2020.00137.
- Zhang M, Ma W, Zhang J, He Y, Wang J. 2018. Analysis of gut microbiota profiles and microbe-disease associations in children with autism spectrum disorders in China. Sci Rep 8:13981. https://doi.org/10.1038/s41598 -018-32219-2.
- Johnson SD, Fox HS, Buch S, Byrareddy SN. 2021. Chronic opioid administration is associated with prevotella-dominated dysbiosis in SIVmac251 infected, cART-treated macaques. J Neuroimmune Pharmacol https://doi .org/10.1007/s11481-021-09993-4.
- Wang F, Meng J, Zhang L, Johnson T, Chen C, Roy S. 2018. Morphine induces changes in the gut microbiome and metabolome in a morphine dependence model. Sci Rep 8:3596. https://doi.org/10.1038/s41598-018-21915-8.
- 29. Lichtbroun M, Jafri F, Chaudhary RS, Batool S, Ahmed J, Lim SH. 2021. High incidence of healthcare facility-acquired Clostridium difficile infections in

chronic opioid users. J Intern Med 289:129–130. https://doi.org/10.1111/ joim.13124.

- Poirier D, Gervais P, Fuchs M, Roussy JF, Paquet-Bolduc B, Trottier S, Longtin J, Loo VG, Longtin Y. 2020. Predictors of Clostridioides difficile infection among asymptomatic, colonized patients: a retrospective cohort study. Clin Infect Dis 70:2103–2210. https://doi.org/10.1093/cid/ciz626.
- Mora AL, Salazar M, Pablo-Caeiro J, Frost CP, Yadav Y, DuPont HL, Garey KW. 2012. Moderate to high use of opioid analgesics are associated with an increased risk of Clostridium difficile infection. Am J Med Sci 343: 277–280. https://doi.org/10.1097/MAJ.0b013e31822f42eb.
- Robinson H, Barrett H, Gomez-Arango L, McIntyre HD, Callaway L, Dekker Nitert M. 2019. Ketonuria is associated with changes to the abundance of Roseburia in the gut microbiota of overweight and obese women at 16 weeks gestation: a cross-sectional observational study. Nutrients 11:1836. https://doi.org/10.3390/nu11081836.
- Ruebel ML, Gilley SP, Sims CR, Zhong Y, Turner D, Chintapalli SV, Piccolo BD, Andres A, Shankar K. 2021. Associations between maternal diet, body composition and gut microbial ecology in pregnancy. Nutrients 13:3295. https://doi.org/10.3390/nu13093295.
- 34. Hu P, Chen X, Chu X, Fan M, Ye Y, Wang Y, Han M, Yang X, Yuan J, Zha L, Zhao B, Yang CX, Qi XR, Ning K, Debelius J, Ye W, Xiong B, Pan XF, Pan A. 2021. Association of gut microbiota during early pregnancy with risk of incident gestational diabetes mellitus. J Clin Endocrinol Metab 106: e4128–e4141. https://doi.org/10.1210/clinem/dgab346.
- Gicquelais RE, Bohnert ASB, Thomas L, Foxman B. 2020. Opioid agonist and antagonist use and the gut microbiota: associations among people in addiction treatment. Sci Rep 10:19471. https://doi.org/10.1038/s41598 -020-76570-9.
- Barengolts E, Green SJ, Eisenberg Y, Akbar A, Reddivari B, Layden BT, Dugas L, Chlipala G. 2018. Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease. PLoS One 13:e0194171. https://doi.org/10.1371/ journal.pone.0194171.
- Fenili D, Brown M, Rappaport R, McLaurin J. 2007. Properties of scyllo-inositol as a therapeutic treatment of AD-like pathology. J Mol Med (Berl) 85: 603–611. https://doi.org/10.1007/s00109-007-0156-7.
- Liu M, Jevtic S, Markham-Coultes K, Ellens NPK, O'Reilly MA, Hynynen K, Aubert I, McLaurin J. 2018. Investigating the efficacy of a combination Aβ-targeted treatment in a mouse model of Alzheimer's disease. Brain Res 1678:138–145. https://doi.org/10.1016/j.brainres.2017.10.015.
- Xia W, Liu G, Shao Z, Xu E, Yuan H, Liu J, Gao L. 2020. Toxicology of tramadol following chronic exposure based on metabolomics of the cerebrum in mice. Sci Rep 10:11130. https://doi.org/10.1038/s41598-020-67974-8.
- Deng Y, Bu Q, Hu Z, Deng P, Yan G, Duan J, Hu C, Zhou J, Shao X, Zhao J, Li Y, Zhu R, Zhao Y, Cen X. 2012. (1) H-nuclear magnetic resonance-based metabonomic analysis of brain in rhesus monkeys with morphine treatment and withdrawal intervention. J Neurosci Res 90:2154–2162. https:// doi.org/10.1002/jnr.23109.
- Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. 2019. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet 58:705–725. https://doi.org/10.1007/s40262-018-00731-3.
- 42. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. 2006. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79:461–479. https://doi.org/10.1016/j.clpt.2006.01.009.
- Mortensen NP, Caffaro MM, Snyder RW, Yueh YL, Fennell TR. 2019. Placental trophoblast transfer of opioids following exposures to individual or mixtures of opioids in vitro. Exp Biol Med (Maywood) 244:846–849. https://doi.org/10.1177/1535370219851109.
- Green MT, Martin RE, Kinkade JA, Schmidt RR, Bivens NJ, Tuteja G, Mao J, Rosenfeld CS. 2020. Maternal oxycodone treatment causes pathophysiological changes in the mouse placenta. Placenta 100:96–110. https://doi .org/10.1016/j.placenta.2020.08.006.
- 45. Rosenfeld CS. 2021. The placenta-brain-axis. J Neurosci Res 99:271–283. https://doi.org/10.1002/jnr.24603.
- 46. Szumlinski KK, Coelho MA, Tran T, Stailey N, Lieberman D, Gabriella I, Swauncy I, Brewin LW, Ferdousian S. 2020. Who is HOT and who is LOT? Detailed characterization of prescription opioid-induced changes in behavior between 129P3/J and 129S1/SvImJ mouse substrains. Genes Brain Behav 19: e12609. https://doi.org/10.1111/gbb.12609.
- Zhang Y, Picetti R, Butelman ER, Schlussman SD, Ho A, Kreek MJ. 2009. Behavioral and neurochemical changes induced by oxycodone differ between adolescent and adult mice. Neuropsychopharmacology 34: 912–922. https://doi.org/10.1038/npp.2008.134.

- Liu YL, Liang JH, Yan LD, Su RB, Wu CF, Gong ZH. 2005. Effects of I-tetrahydropalmatine on locomotor sensitization to oxycodone in mice. Acta Pharmacol Sin 26:533–538. https://doi.org/10.1111/j.1745-7254.2005.00101.x.
- Mao J, Zhang X, Sieli PT, Falduto MT, Torres KE, Rosenfeld CS. 2010. Contrasting effects of different maternal diets on sexually dimorphic gene expression in the murine placenta. Proc Natl Acad Sci U S A 107:5557–5562. https://doi.org/10.1073/pnas.1000440107.
- 50. Mao J, Jain A, Denslow ND, Nouri MZ, Chen S, Wang T, Zhu N, Koh J, Sarma SJ, Sumner BW, Lei Z, Sumner LW, Bivens NJ, Roberts RM, Tuteja G, Rosenfeld CS. 2020. Bisphenol A and bisphenol S disruptions of the mouse placenta and potential effects on the placenta-brain axis. Proc Natl Acad Sci U S A 117:4642–4652. https://doi.org/10.1073/pnas.1919563117.
- Ma J, Prince AL, Bader D, Hu M, Ganu R, Baquero K, Blundell P, Alan Harris R, Frias AE, Grove KL, Aagaard KM. 2014. High-fat maternal diet during pregnancy persistently alters the offspring microbiome in a primate model. Nat Commun 5:3889. https://doi.org/10.1038/ncomms4889.
- 52. Thorburn AN, McKenzie CI, Shen S, Stanley D, Macia L, Mason LJ, Roberts LK, Wong CHY, Shim R, Robert R, Chevalier N, Tan JK, Mariño E, Moore RJ, Wong L, McConville MJ, Tull DL, Wood LG, Murphy VE, Mattes J, Gibson PG, Mackay CR. 2015. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat Commun 6:7320. https://doi.org/10.1038/ncomms8320.
- 53. Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Lozupone CA, Turnbaugh PJ, Fierer N, Knight R. 2011. Global patterns of 16S rRNA diversity at a depth of millions of sequences per sample. Proc Natl Acad Sci U S A 108:4516–4522. https://doi.org/10.1073/pnas.1000080107.
- Walters WA, Caporaso JG, Lauber CL, Berg-Lyons D, Fierer N, Knight R. 2011. PrimerProspector: de novo design and taxonomic analysis of barcoded polymerase chain reaction primers. Bioinformatics 27:1159–1161. https://doi.org/10.1093/bioinformatics/btr087.
- 55. Javurek AB, Spollen WG, Johnson SA, Bivens NJ, Bromert KH, Givan SA, Rosenfeld CS. 2016. Effects of exposure to bisphenol A and ethinyl estradiol on the gut microbiota of parents and their offspring in a rodent model. Gut Microbes 7:471–485. https://doi.org/10.1080/19490976.2016 .1234657.
- 56. Koestel ZL, Backus RC, Tsuruta K, Spollen WG, Johnson SA, Javurek AB, Ellersieck MR, Wiedmeyer CE, Kannan K, Xue J, Bivens NJ, Givan SA, Rosenfeld CS. 2017. Bisphenol A (BPA) in the serum of pet dogs following short-term consumption of canned dog food and potential health consequences of exposure to BPA. Sci Total Environ 579:1804–1814. https://doi .org/10.1016/j.scitotenv.2016.11.162.
- 57. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, Bai Y, Bisanz JE, Bittinger K, Brejnrod A, Brislawn CJ, Brown CT, Callahan BJ, Caraballo-Rodríguez AM, Chase J, Cope EK, Da Silva R, Diener C, Dorrestein PC, Douglas GM, Durall DM, Duvallet C, Edwardson CF, Ernst M, Estaki M, Fouquier J, Gauglitz JM, Gibbons SM, Gibson DL, Gonzalez A, Gorlick K, Guo J, Hillmann B, Holmes S, Holste H, Huttenhower C, Huttley GA, Janssen S, Jarmusch AK, Jiang L, Kaehler BD, Kang KB, Keefe CR, Keim P, Kelley ST, Knights D, et al. 2019. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 37:852–857. https://doi.org/10.1038/ s41587-019-0209-9.
- Paulson JN, Pop M, Bravo HC. 2013. metagenomeSeq: statistical analysis for sparse high-throughput sequencing. Bioconductor package 1:191.
- Douglas GM, Maffei VJ, Zaneveld JR, Yurgel SN, Brown JR, Taylor CM, Huttenhower C, Langille MGI. 2020. PICRUSt2 for prediction of metagenome functions. Nat Biotechnol 38:685–688. https://doi.org/10.1038/ s41587-020-0548-6.
- Barbera P, Kozlov AM, Czech L, Morel B, Darriba D, Flouri T, Stamatakis A. 2019. EPA-ng: massively parallel evolutionary placement of genetic sequences. Syst Biol 68:365–369. https://doi.org/10.1093/sysbio/syy054.
- Czech L, Barbera P, Stamatakis A. 2020. Genesis and Gappa: processing, analyzing and visualizing phylogenetic (placement) data. Bioinformatics 36:3263–3265. https://doi.org/10.1093/bioinformatics/btaa070.
- 62. Mirarab S, Nguyen N, Warnow T. 2012. SEPP: SATé-enabled phylogenetic placement. Pac Symp Biocomput https://doi.org/10.1142/9789814366496 _0024:247-58.
- Louca S, Doebeli M. 2018. Efficient comparative phylogenetics on large trees. Bioinformatics 34:1053–1055. https://doi.org/10.1093/bioinformatics/ btx701.
- 64. Ye Y, Doak TG. 2009. A parsimony approach to biological pathway reconstruction/inference for genomes and metagenomes. PLoS Comput Biol 5: e1000465. https://doi.org/10.1371/journal.pcbi.1000465.

- 65. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8.
- 66. Javurek AB, Spollen WG, Ali AM, Johnson SA, Lubahn DB, Bivens NJ, Bromert KH, Ellersieck MR, Givan SA, Rosenfeld CS. 2016. Discovery of a novel seminal fluid microbiome and influence of estrogen receptor alpha genetic status. Sci Rep 6:23027. https://doi.org/10.1038/srep23027.
- Javurek AB, Suresh D, Spollen WG, Hart ML, Hansen SA, Ellersieck MR, Bivens NJ, Givan SA, Upendran A, Kannan R, Rosenfeld CS. 2017.

Gut dysbiosis and neurobehavioral alterations in rats exposed to silver nanoparticles. Sci Rep 7:2822. https://doi.org/10.1038/s41598-017 -02880-0.

- Rohart F, Gautier B, Singh A, Lê Cao K-A. 2017. mixOmics: an R package for 'omics feature selection and multiple data integration. PLoS Comput Biol 13:e1005752. https://doi.org/10.1371/journal.pcbi.1005752.
- Gonzalez I, Cao KA, Davis MJ, Dejean S. 2012. Visualising associations between paired' omics' data sets. BioData Min 5(1):19. https://biodatamining .biomedcentral.com/articles/10.1186/1756-0381-5-19.